Early vs delayed ASCT
| Ref. . | Year . | Study type . | Induction regimen (early ASCT vs delayed ASCT) . | Response (early vs delayed ASCT) . | PFS (early vs delayed ASCT) . | OS (early vs delayed ASCT) . |
|---|---|---|---|---|---|---|
| Fermand et al13 | 1998 | P | VAMP × 3-4 cycles and ASCT vs VMCP until plateau and ASCT at relapse | 85.7% vs 55.5% | 39 mo vs 13 mo | 64.6 mo vs 64 mo (P = .92) |
| Attal et al16 | 2017 | P | VRD × 3 cycles and ASCT + VRD × 2 cycles vs VRD × 8 cycles and ASCT at relapse | CR: 59% vs 48% (P = .03) | 50 mo vs 36 mo (P < .01) | 4 y: 81% vs 82% |
| Kumar et al24 | 2012 | r | TD or RD × 4-6 cycles followed by early or delayed ASCT | 20 mo vs 16 mo (P = NS) | 4 y: 73% vs 73% (P = .3) | |
| Dunavin et al23 | 2013 | r | T-, R-, or V-based induction followed by early or delayed ASCT | ≥VGPR: 77% vs 55% (P < .01) | 28 mo vs 18 mo (P = .11) | NR vs 83 mo (P = .45) |
| Remenyi et al25 | 2016 | r | 57% in early ASCT and 53.2% in delayed ASCT group received novel therapies | CR: 58.1% vs 46.8% (P = .016) | 30.2 mo vs 23.3 mo (P = .036) | 97.2 mo vs 99.1 mo (P = .77) |
| Ref. . | Year . | Study type . | Induction regimen (early ASCT vs delayed ASCT) . | Response (early vs delayed ASCT) . | PFS (early vs delayed ASCT) . | OS (early vs delayed ASCT) . |
|---|---|---|---|---|---|---|
| Fermand et al13 | 1998 | P | VAMP × 3-4 cycles and ASCT vs VMCP until plateau and ASCT at relapse | 85.7% vs 55.5% | 39 mo vs 13 mo | 64.6 mo vs 64 mo (P = .92) |
| Attal et al16 | 2017 | P | VRD × 3 cycles and ASCT + VRD × 2 cycles vs VRD × 8 cycles and ASCT at relapse | CR: 59% vs 48% (P = .03) | 50 mo vs 36 mo (P < .01) | 4 y: 81% vs 82% |
| Kumar et al24 | 2012 | r | TD or RD × 4-6 cycles followed by early or delayed ASCT | 20 mo vs 16 mo (P = NS) | 4 y: 73% vs 73% (P = .3) | |
| Dunavin et al23 | 2013 | r | T-, R-, or V-based induction followed by early or delayed ASCT | ≥VGPR: 77% vs 55% (P < .01) | 28 mo vs 18 mo (P = .11) | NR vs 83 mo (P = .45) |
| Remenyi et al25 | 2016 | r | 57% in early ASCT and 53.2% in delayed ASCT group received novel therapies | CR: 58.1% vs 46.8% (P = .016) | 30.2 mo vs 23.3 mo (P = .036) | 97.2 mo vs 99.1 mo (P = .77) |
CR, complete response; NR, not reached; NS, nonsignificant; P, prospective; r, retrospective; R, Revlimid; RD, Revlimid, dexamethasone; Ref., reference; T, thalidomide; TD, thalidomide, dexamethasone; V, Velcade; VAMP, vincristine, Adriamycin, melphalan, prednisolone; VGPR, very good partial response; VMCP, vincristine, melphalan, cyclophosphamide, prednisolone; VRD, Velcade, Revlimid, dexamethasone.